Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Cancer
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16,...
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm...
UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Bio-Path Holdings Provides Clinical and Operational Update
Company Expects to Achieve Several Near-Term Clinical MilestonesHOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human...
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK,...
IBA is looking for 100 new collaborators in Belgium by June 2023
Louvain-la-Neuve, Belgium, 14 March 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology wants...
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
New Business Strategy Focused on Precision OncologyLONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:...
Custom Research Presented at AMIA Informatics Summit Reveals Promising Findings for Healthcare Innovation
SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a “Buy” Recommendation
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation...
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results...
Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing’s Sarcoma
-Pilot study in Ewing's Sarcoma supports the therapeutic potential of Vigil in multiple solid tumor types- -Circulating tumor DNA levels,...
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Media Release Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA...
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Initiation of APEX Part 2 planned for mid-2023Updated clinical data from Phase 3 PEAK lead-in in GIST patients expected 1H23Initial...
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
Company maintains strong cash position of $249.1 millionSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
EMulate Therapeutics Announces the Addition of Donna Morgan Murray, Ph.D., to its Board of Directors
BELLEVUE, Wash., March 14, 2023 (GLOBE NEWSWIRE) -- EMulate Therapeutics, Inc. (“EMulate” or the “Company”) a clinical-stage company, developing digital...
H1 Launches Advanced Diversity Insights and Clinical Trial Performance Insights
First to offer diversity insights, healthcare data leader H1 expands its offering with two new capabilities focused on supporting diversity...
First Use of the Galaxy System™ in Human Patients Conducted at Macquarie University Hospital in Australia
Next generation, integrated solution for navigated robotic bronchoscopy is now FDA clearedSAN CARLOS, Calif., March 13, 2023 (GLOBE NEWSWIRE) --...